Exhibit 10.3 Execution Version COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (the "Agreement"), dated as of November [13], 2024, by and among Exicure, Inc., a Delaware corporation (the "Company"), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a "Purchaser" and together, the "Purchasers"). Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.6. RECITALS A. The Company and the Purchas ...

Exhibit 99.1 NEWS FROM For more information contact: Kate Lowrey - VP of Investor Relations (314) 213-7277 / klowrey@escotechnologies.com ESCO REPORTS FOURTH QUARTER AND FISCAL 2024 RESULTS - Q4 Sales increase 9.5% to $299 Million - Q4 GAAP EPS increase 6.5% to $1.32 - - Q4 Adjusted EPS increase 16.8% to $1.46 - - FY 2024 Sales increase 7.4% to $1.0 Billion - - FY 2024 Entered Orders increase 9.7% to $1.1 Billion - - FY 2024 GAAP EPS increase 10.1% to $3.94 - - FY 2024 Adjusted EPS increase 13.0% to $4.18 - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 1-13752 | --- | --- | --- | |-----------------------------------------------------------------------------|----------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File No.: 001-37703 IZEA WORLDWIDE, INC. (Exact name of registrant as specified in its charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------|------------|-------|-------------------------|----------------------------- ...

Table of Contents GRI BIO, INC. ____________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________ FORM 10-Q ____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Septe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41013 GCT Semiconductor Holding, Inc. (Exact Name of Registrant as Specified in its ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41013 GCT Semiconductor Holding, Inc. (Exact Name of Registrant as Specified in its ...

Exhibit 99 Movano Health Reports Q3 2024 Financial Results and Provides Business Update Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif. – November 14, 2024 – Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focus ...

Title of Each Class: Trading Symbol(s) Name of Each Exchange on Which Registered: Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant DPCSU The Nasdaq Stock Market LLC Class A ordinary share, $0.0001 par value DPCS The Nasdaq Stock Market LLC Redeemable public warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 DPCSW The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi ...